Joslin researchers gain new understanding of diabetes and kidney disease

July 23, 2012, Joslin Diabetes Center

Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes. The findings, which are reported today online by Diabetes, may lead to the development of new therapeutic agents that harness the actions of GLP-1 to prevent the harmful effects of hyperglycemia on renal endothelial cells.

, also known as , are one of the most life-threatening complications of diabetes that often lead over time to end-stage (ESRD). About a half million people in the US – 44 percent of whom are diabetics -- have ESRD, which requires dialysis or kidney transplantation. As a result, investigating the relationship of diabetes to renal dysfunction is a major focus of diabetes research. "We are very eager to develop new treatments for diabetic ," says George King, M.D., lead author of the study, and chief scientific officer, head of the Dianne Nunnally Hoppes Laboratory for Diabetes Complications and a professor of medicine at Harvard Medical School.

GLP-1 is an incretin hormone that is produced by the intestine in response to food. GLP-1 increases the secretion of insulin from the pancreas, slows absorption of glucose from the gut, and reduces the action of – all of which lower glucose levels in the blood. In addition, GLP-1 reduces appetite. The drug, exendin-4 (marketed as Exenatide), which mimics the effects of GLP-1, is used to lower blood glucose in type 2 diabetes.

Recent studies have reported that GLP-1 improves the function of renal endothelial cells (which regulate blood clotting, immune response and blood vessel activity, among other critical functions, and are impaired by insulin resistance) and can prevent some renal pathologies in diabetic rodents. GLP-1 receptors (GLP-1R), which are abundant in the intestine, are also found in the endothelium and kidney.

The Joslin study investigated the effects of GLP-1 in non-diabetic and diabetic mice with an "overexpression" of the enzyme PKCβ (protein kinase C-beta) which is produced in excess when blood glucose is high. Excess PKCβ can lead to diabetes complications, including kidney disease. PKCβ enhances the action of angiotensin II (Ang II), a peptide hormone that affects renal filtration and blood flow and also regulates blood pressure, which increases inflammation and accelerates the progression of kidney damage.

The study looked at the interactions of GLP-1, PKC-beta and ANG II that affect GLP-1's protective action in renal endothelial cells. "We've been interested in diabetic kidney disease for a long time, particularly the role of PKCβ and Ang II in promoting kidney damage," says Dr. King. "We were interested in investigating how GLP-1 could protect against the effects of hyperglycemia on renal function."

Josin researchers made two major findings: They identified the mechanisms by which GLP-1 can induce protective actions on the glomerular (renal) endothelial cells by inhibiting the signaling pathway of Ang II and its pro-inflammatory effect; and demonstrated a dual signaling mechanism by which hyperglycemia, via PKCβ activation, can increase Ang II action and inhibit GLP-1's protective effects by reducing the expression of GLP-1 receptors in the glomerular . "We know that people with are more sensitive to Ang II; our data suggests one reason why," says Dr. King.

The results suggest that effective could be developed to enhance the effects of GLP-1R on the endothelium which may prevent glomerular endothelial dysfunction and slow the progression of diabetic nephropathy. "We now know that increased PKCβ decreases GLP-1R which makes the kidney less responsive to treatment with GLP-1-based drugs. Possible new treatments could combine PKCβ inhibitors with higher doses of GLP-1 agonists. GLP-1 is one potential pharmaceutical that could both lower glucose and minimize the toxic effects of Ang II to lower the risk of kidney diseases," says Dr. King.

Explore further: Importance of diabetes genetic variants unclear

Related Stories

Importance of diabetes genetic variants unclear

April 4, 2012
(HealthDay) -- Genetic variants associated with type 2 diabetes that affect glucagon-like peptide 1 (GLP-1) are not associated with GLP-1 levels or GLP-1-induced insulin secretion in healthy individuals, according to a study ...

Gut hormone leads to weight loss in overweight or obese patients

January 10, 2012
Giving overweight or obese patients a gut hormone that suppresses appetite leads to clinically beneficial weight loss as well as reduced blood pressure and cholesterol levels, finds a study published in the British Medical ...

Diet soda linked to increase in glucagon-like peptide 1 levels

March 22, 2012
(HealthDay) -- Drinking a diet soda before a glucose load is associated with increased glucagon-like peptide 1 (GLP-1) secretion in individuals with type 1 diabetes and healthy controls, but not in those with type 2 diabetes, ...

Research reveals hormone action that could lead to treatments for type 2 diabetes

September 30, 2011
(Medical Xpress) -- Researchers at the University of Cincinnati have discovered that the immediate improvement in blood sugar (blood glucose) for those with type 2 diabetes who undergo gastric bypass surgery is related to ...

Improving psoriasis with GLP-1 analogue therapy

December 13, 2011
(Medical Xpress) -- UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following ...

Bile acids may hold clue to treat heart disease

December 6, 2011
Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation. The ...

Recommended for you

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.

Human protein may aid neuron invasion by virus that causes hand, foot, and mouth disease

January 11, 2018
A human protein known as prohibitin may play a significant role in infection of the nervous system by EV71, one of several viruses that can cause hand, foot, and mouth disease. Issac Too of the National University of Singapore ...

Untangling how Epstein-Barr virus infects cells

January 11, 2018
A team led by scientists at Northwestern Medicine has discovered a new epithelial receptor for Epstein-Barr virus, according to a study published recently in Nature Microbiology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.